Stay updated on SGN-PDL1V in Advanced Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the SGN-PDL1V in Advanced Solid Tumors Clinical Trial page.

Latest updates to the SGN-PDL1V in Advanced Solid Tumors Clinical Trial page
- CheckyesterdayChange DetectedRevision updated to v3.5.4, replacing v3.5.3. This indicates a new version of the page with minor edits rather than changes to the study data.SummaryDifference0.0%

- Check8 days agoNo Change Detected
- Check15 days agoNo Change Detected
- Check23 days agoChange DetectedThe page’s metadata reflects a newer update and the site’s revision version has changed (from `v3.5.2` to `v3.5.3`), with related update dates adjusted accordingly. No changes to the core study details (e.g., eligibility criteria, interventions, outcomes, or recruiting locations) are indicated.SummaryDifference0.2%

- Check30 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2. This appears to be a backend/maintenance version bump with no visible changes to the study details.SummaryDifference0.0%

- Check59 days agoChange DetectedHepatocellular carcinoma was added to the list of conditions, and the page revision was updated from v3.4.3 to v3.5.0.SummaryDifference0.1%

- Check66 days agoChange DetectedRevision: v3.4.3 is now displayed, replacing the previous v3.4.2.SummaryDifference0.0%

- Check80 days agoChange DetectedAdded hepatocellular carcinoma, endometrial cancer, and pancreatic adenocarcinoma as study indications; updated the study locations to 61 sites.SummaryDifference2%

Stay in the know with updates to SGN-PDL1V in Advanced Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the SGN-PDL1V in Advanced Solid Tumors Clinical Trial page.